Skip to main content
DrugPrice

Diabetes Medications

Includes insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and metformin. The highest-growth drug class by Medicare spending.

$4.00
Cheapest Option
$685.00
Most Expensive
13
Drugs Tracked
$555.00
Price Range

How Diabetes Medications Work

Metformin reduces liver glucose production ($4/month generic). GLP-1 agonists (Ozempic, Trulicity) mimic gut hormones to stimulate insulin release and reduce appetite. SGLT2 inhibitors (Jardiance, Farxiga) block glucose reabsorption in kidneys. DPP-4 inhibitors (Januvia) enhance the body's own incretin hormones. Insulin directly replaces what the body can't produce.

Diabetes Medications — Ranked by Cost Per Claim (Cheapest First)

#DrugGeneric NameCost/ClaimGeneric?
1BasaglarInsulin Glargine (biosimilar)$130.00No
2LantusInsulin Glargine$136.00Yes
3NovoLogInsulin Aspart$139.00Yes
4HumalogInsulin Lispro$142.00Yes
5JardianceEmpagliflozin$210.00Yes
6JanuviaSitagliptin$219.00No
7ToujeoInsulin Glargine U-300$254.00Yes
8TresibaInsulin Degludec$262.00Yes
9FarxigaDapagliflozin$266.00Yes
10RybelsusSemaglutide (oral)$428.00Yes
11TrulicityDulaglutide$473.00No
12MounjaroTirzepatide$673.00No
13OzempicSemaglutide$685.00No

Potential Savings

Metformin ($4/month) remains the first-line treatment for Type 2 diabetes. Newer GLP-1 agonists cost $400-900/month but Medicare has negotiated Ozempic down to $274/month starting 2027 — a 71% discount.

First-line generic: metformin at $4.00/claim. Ask your doctor if this is appropriate for you.

Key Facts

  • 1.37.3 million Americans have diabetes (11.3% of the population)
  • 2.GLP-1 agonists (Ozempic, Mounjaro) are the fastest-growing drug class by spending — up 72.5% YoY
  • 3.Medicare negotiated 2027 prices for Ozempic ($274/mo), Jardiance ($197/mo), and Januvia ($113/mo)
  • 4.Insulin prices capped at $35/month for Medicare beneficiaries since 2023
  • 5.Total Medicare diabetes drug spending exceeds $20B annually

Frequently Asked Questions

The cheapest option is Metformin (generic Glucophage) at $4 per claim. Metformin ($4/month) remains the first-line treatment for Type 2 diabetes. Newer GLP-1 agonists cost $400-900/month but Medicare has negotiated Ozempic down to $274/month starting 2027 — a 71% discount.

Metformin reduces liver glucose production ($4/month generic). GLP-1 agonists (Ozempic, Trulicity) mimic gut hormones to stimulate insulin release and reduce appetite. SGLT2 inhibitors (Jardiance, Farxiga) block glucose reabsorption in kidneys. DPP-4 inhibitors (Januvia) enhance the body's own incretin hormones. Insulin directly replaces what the body can't produce.

All spending data comes from the CMS Medicare Part D Drug Spending Dashboard. Patent and generic information comes from the FDA Orange Book. Prices shown are average cost per 30-day supply claim under Medicare Part D.